Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atea Pharmaceuticals Inc AVIR

Healthcare
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is... see more

Recent & Breaking News (NDAQ:AVIR)

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

GlobeNewswire November 13, 2023

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 8, 2023

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

GlobeNewswire November 8, 2023

Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

GlobeNewswire November 2, 2023

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023

GlobeNewswire November 1, 2023

Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

GlobeNewswire September 6, 2023

Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 8, 2023

Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

GlobeNewswire August 1, 2023

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

GlobeNewswire June 15, 2023

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

GlobeNewswire June 5, 2023

Atea Pharmaceuticals' Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences

GlobeNewswire May 30, 2023

Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences

GlobeNewswire May 23, 2023

Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 8, 2023

Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023

GlobeNewswire May 1, 2023

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19

GlobeNewswire April 25, 2023

Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases

GlobeNewswire April 12, 2023

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research

GlobeNewswire March 14, 2023

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research

GlobeNewswire March 8, 2023

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire February 28, 2023